A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.

ABSTRACT:

Introduction

Clinical evidence suggests that first-line immune checkpoint inhibitor (ICI) combination therapies can improve survival in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC). However, the optimal strategy remains unknown without a systematic comparison of their long-term effects.

Methods

We performed a systematic review and network meta-analysis by retrieving up-to-date literature from PubMed^® (National Library of Medicine, Bethesda, MD, USA), Embase^® (Elsevier, Amsterdam, Netherlands), MEDLINE^® (National Library of Medicine), ClinicalTrials.gov (National Library of Medicine), and major international conference publications. Published studies and abstracts comparing first-line ICI combination therapies wit

SUBMITTER: Shao T 

PROVIDER: S-EPMC9645411 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature